Explore Our Network

Explore MTEC's network of innovators, investors, and research organizations—along with patents and funding opportunities—advancing medical technologies for military and civilian health.

government (1)

Buchmeier, Michael (1)

Rosenberg, Steven A. (71)

Dimitrov, Dimiter S. (63)

Sarepta Therapeutics Inc (1)

Scripps Research Institute (1)

US Department of Health and Human Services (1)

B2 (1)

2009 (1)

Showing 1 Patents

Compounds are substantially uncharged morpholino oligonucleotides having a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with viral RNA sequences within a 19 nucleotide region of the 5'-terminal regions of the viral RNA

01-09-2009 • US-7582615-B2

NEUMAN, BENJAMIN • STEIN, DAVID A. • BUCHMEIER, MICHAEL • IVERSEN, PATRICK L.

Scripps Research Institute • Sarepta Therapeutics Inc • US Department of Health and Human Services

government (1)

Buchmeier, Michael (1)

Rosenberg, Steven A. (71)

Dimitrov, Dimiter S. (63)

Sarepta Therapeutics Inc (1)

Scripps Research Institute (1)

US Department of Health and Human Services (1)

B2 (1)

2009 (1)

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.

MTEC

For federal
agencies

Focus Areas Technology Showcase Member Directory Events

For innovators and
service providers

Member Directory Submitting Proposals Active Solicitations How to Join

For healthcare
investors

Investor Directory Technology Showcase How to Join

About
MTEC

Who We Are Capabilities Events Resources Contact Us

The Internal Revenue Service has recognized MTEC as a charitable organization which is exempt under Internal Revenue Code Section 501(c)(3).

Explore Our Network

Owner

Inventors

Assignee